Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.32), $0.02 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $10.95 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.